Orphazyme A/S is a Danish biotech company. It is engaged in the development of paradigm-changing medicines for the treatment of protein misfolding diseases. The company's lead candidate, arimoclomol, is in development for four severe orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis and Amyotrophic Lateral Sclerosis, and two lysosomal storage diseases, Niemann-Pick disease Type C and Gaucher disease.
| Website: | www.orphazyme.com |
| Email: | investor@tubemogul.com |
| Main Phone: | +45 39178272 |
| Address: | Ole Maaloes Vej 3 |
| Address 2: | Suite 2 |
| State: | CA |
| City / Town: | Copenhagen |
| Country: | DK |
| Postal Code: | DK-2200 |
| Exchange: | NGS |
| Employees: | 114 |
| NAICS: | Software Publishers(511210) |
Complete IPO calendar HERE (1) Based in Beltsville, MD, TerraForm Power ($TERP) scheduled a $401 million IPO on the Nasdaq with a market capitalization of $1.87 billion at a price range
The bull market that began in early March 2009 has yet to enter a speculation phase and yet to attract the individual investor, so more upside can be expected.That does not preclude a sharp
Orphazyme A/S is a Danish biotech company. It is engaged in the development of paradigm-changing medicines for the treatment of protein misfolding diseases. The company's lead candidate, arimoclomol, is in development for four severe orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis and Amyotrophic Lateral Sclerosis, and two lysosomal storage diseases, Niemann-Pick disease Type C and Gaucher disease.
| Website: | www.orphazyme.com |
| Email: | investor@tubemogul.com |
| Main Phone: | +45 39178272 |
| Address: | Ole Maaloes Vej 3 |
| Address 2: | Suite 2 |
| State: | CA |
| City / Town: | Copenhagen |
| Country: | DK |
| Postal Code: | DK-2200 |
| Exchange: | NGS |
| Employees: | 114 |
| NAICS: | Software Publishers(511210) |
Complete IPO calendar HERE (1) Based in Beltsville, MD, TerraForm Power ($TERP) scheduled a $401 million IPO on the Nasdaq with a market capitalization of $1.87 billion at a price range
The bull market that began in early March 2009 has yet to enter a speculation phase and yet to attract the individual investor, so more upside can be expected.That does not preclude a sharp
| Last Price 14.00 | Change $ 0. | Change % 0.00 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open N/A | High N/A | Low N/A | Prev Close 14.00 |
| Last Trade | Volume 0 | 52 Wk Hi 14.46 | 52 Wk Low 7.00 |
| Market Cap 379.1 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 27,079,630.00 | EPS (TTM) -1.77 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 0 |
| Number of Buys | 0 | 0 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 0 |
| Last 10 Buys | Shares |
|---|---|
| Brett Wilson | 1,000 |
| Chip Scovic | 1,000 |
| John Hughes | 1,000 |
| Brett Wilson | 1,000 |
| Jack R. Lazar | 1,000 |
| Brett Wilson | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Keith Eadie | 1,000 |
| Brett Wilson | 1,000 |
| Brett Wilson | 1,000 |
| William B. Elmore | 1,000 |
| William B. Elmore | 1,000 |
| William B. Elmore | 1,000 |
| William B. Elmore | 1,000 |
| William B. Elmore | 1,000 |
| William B. Elmore | 1,000 |
| William B. Elmore | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 17 | 17 | 17 | 17 |
| Low Target Price Estimate | 11 | 11 | 11 | 11 |
| Mean Target Price Estimate | 14.29 | 14.29 | 14.29 | 14.29 |
| Standard Deviation | 1.89 | 1.89 | 1.89 | 1.89 |
| Date of Most Recent Estimate | 11/17/16 | 11/17/16 | 11/17/16 | 11/17/16 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| SC 13D/A | Amendment to a SC 13D filing | 17 | 2017-01-10 |
| SC 13D/A | Amendment to a SC 13D filing | 6 | 2017-01-09 |
| 15-12B | Termination of registration under Section 12(b) or suspension of duty to file reports | 1 | 2016-12-29 |
| SC 13D/A | Amendment to a SC 13D filing | 6 | 2016-12-22 |
| S-8 POS | Post-effective amendment to an S-8 filing | 3 | 2016-12-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-12-22 |
| S-8 POS | Post-effective amendment to an S-8 filing | 3 | 2016-12-22 |
| S-8 POS | Post-effective amendment to an S-8 filing | 3 | 2016-12-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-12-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-12-22 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 3 | 3 | 6 | 4 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 8 | 9 | 4 | 4 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.45 | 2.5 | 1.8 | 2 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait